Genprex, INC. (GNPX) — SEC Filings

Overview

Genprex, INC. (GNPX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 21, 2026: On April 21, 2026, Genprex, Inc. filed an 8-K report detailing events from March 29, 2026. The filing includes information under Regulation FD Disclosure and Other Events, along with financial statements and exhibits. The report primarily consists of various graphic files, suggesting a presentation

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 7 bearish, 40 neutral, 3 mixed. The dominant filing sentiment for Genprex, INC. is neutral.

Filing Type Overview

Genprex, INC. (GNPX) has filed 1 4, 37 8-K, 5 10-Q, 2 S-1, 1 DEF 14A, 1 10-K, 1 SC 13G/A, 2 SC 13G with the SEC between Aug 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Genprex, Inc. Files 8-K with Presentation Materials — 8-K · Apr 21, 2026 Risk: low
  On April 21, 2026, Genprex, Inc. filed an 8-K report detailing events from March 29, 2026. The filing includes information under Regulation FD Disclosure and Ot
• 4 Filing — 4 · Apr 15, 2026
• Genprex, Inc. Files 8-K on Dec 23, 2025 — 8-K · Dec 23, 2025 Risk: low
  Genprex, Inc. filed an 8-K on December 23, 2025, reporting on other events and financial statements. The filing details the company's corporate structure, inclu
• Genprex, Inc. Files 8-K on Delisting Notice — 8-K · Nov 26, 2025 Risk: high
  Genprex, Inc. filed an 8-K on November 26, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard, and also filed fina
• Genprex, Inc. Files 8-K Report — 8-K · Nov 21, 2025 Risk: low
  On November 21, 2025, Genprex, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating update
• 8-K Filing — 8-K · Nov 19, 2025
• 8-K Filing — 8-K · Nov 18, 2025
• Genprex Narrows Q3 Loss, Boosts Cash from Offerings Amid Clinical Progress — 10-Q · Nov 14, 2025 Risk: high
  Genprex, Inc. (GNPX) reported a net loss of $3,799,240 for the three months ended September 30, 2025, a 11.97% improvement from the $4,315,987 net loss in the s
• 8-K Filing — 8-K · Nov 4, 2025
• Genprex, Inc. Files 8-K: Material Agreement, Equity Sales — 8-K · Oct 29, 2025 Risk: medium
  Genprex, Inc. filed an 8-K on October 29, 2025, reporting on events as of October 28, 2025. The filing indicates the entry into a material definitive agreement,
• Genprex, Inc. Files 8-K — 8-K · Oct 28, 2025 Risk: low
  Genprex, Inc. filed an 8-K on October 28, 2025, reporting other events and financial statements. The company, incorporated in Delaware with its principal execut
• Genprex, Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Oct 24, 2025 Risk: medium
  Genprex, Inc. announced on October 23, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity sec
• Genprex, Inc. Files 8-K Report — 8-K · Oct 23, 2025 Risk: low
  Genprex, Inc. filed an 8-K on October 23, 2025, reporting other events and financial statements. The company, incorporated in Delaware with its principal execut
• Genprex, Inc. Files 8-K: Other Events & Financials — 8-K · Oct 21, 2025 Risk: low
  Genprex, Inc. filed an 8-K on October 21, 2025, reporting other events and financial statements. The company, incorporated in Delaware with its principal execut
• Genprex Faces Delisting Concerns, Files 8-K — 8-K · Oct 17, 2025 Risk: high
  Genprex, Inc. filed an 8-K on October 17, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The filing also covers material m
• Genprex S-1: Lincoln Park to Resell 25M Shares; Oncology Trials Advance — S-1 · Sep 12, 2025 Risk: high
  Genprex, Inc. (GNPX) filed an S-1 to register the resale of up to 25,000,000 shares of common stock by Lincoln Park Capital Fund, LLC, stemming from a Purchase
• Genprex, Inc. Files 8-K Amid Listing Concerns — 8-K · Aug 20, 2025 Risk: high
  Genprex, Inc. filed an 8-K on August 20, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing also includes financia
• Genprex, Inc. Files 8-K Report — 8-K · Aug 18, 2025 Risk: low
  On August 18, 2025, Genprex, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates
• Genprex, Inc. Files 8-K: Officer/Director Changes & Shareholder Votes — 8-K · Aug 15, 2025 Risk: medium
  Genprex, Inc. filed an 8-K on August 15, 2025, reporting on several key events. These include the departure of directors or certain officers, the election of di
• Genprex Narrows Q2 Loss Amidst Clinical Trial Progress, Cash Declines — 10-Q · Aug 14, 2025 Risk: high
  Genprex, Inc. (GNPX) reported a net loss of $4,674,901 for the three months ended June 30, 2025, an improvement from a net loss of $6,495,845 in the same period
• Genprex, Inc. Files 8-K with Regulatory and Financial Updates — 8-K · Aug 4, 2025 Risk: low
  Genprex, Inc. filed an 8-K on August 4, 2025, reporting on events that occurred on the same date. The filing includes information related to Regulation FD Discl
• Genprex Proposes Reverse Stock Split, Equity Plan Revamp Ahead of Annual Meeting — DEF 14A · Jul 16, 2025 Risk: high
  Genprex, Inc. (GNPX) filed a DEF 14A on July 16, 2025, outlining proposals for its Annual Meeting on August 15, 2025. Key proposals include the election of one
• Genprex, Inc. Files 8-K Reporting Corporate Details — 8-K · Jun 24, 2025 Risk: low
  Genprex, Inc. filed an 8-K on June 24, 2025, reporting other events and financial statements. The filing details the company's corporate structure, including it
• Genprex, Inc. Files 8-K Reporting Corporate Details — 8-K · Jun 23, 2025 Risk: low
  Genprex, Inc. filed an 8-K on June 23, 2025, reporting other events and financial statements. The filing details the company's corporate structure, including it
• Genprex, Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Jun 11, 2025 Risk: medium
  Genprex, Inc. filed an 8-K on June 11, 2025, reporting an entry into a material definitive agreement and unregistered sales of equity securities. The filing als
• Genprex, Inc. Files 8-K on Delisting Notice — 8-K · Jun 9, 2025 Risk: high
  Genprex, Inc. filed an 8-K on June 6, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard, and also filed financial
• Genprex Files S-1 Registration Statement — S-1 · May 14, 2025 Risk: medium
  Genprex, Inc. filed an S-1 registration statement on May 14, 2025, to register securities under the Securities Act of 1933. The company, headquartered in Austin
• Genprex Q1 2025 10-Q: Minimal Revenue, Assets Detailed — 10-Q · May 12, 2025 Risk: medium
  Genprex, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported minimal revenue for the first quarter of 2025, with $0.001 million in bo
• Genprex, Inc. Files 8-K Report — 8-K · May 7, 2025 Risk: low
  On May 7, 2025, Genprex, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or d
• Genprex, Inc. Files 8-K Report — 8-K · May 6, 2025 Risk: low
  On May 6, 2025, Genprex, Inc. filed an 8-K report. The filing primarily concerns the company's financial statements and exhibits, with no specific material even
• Genprex, Inc. Files 8-K: Corporate Details & Financials — 8-K · Apr 28, 2025 Risk: low
  Genprex, Inc. filed an 8-K on April 28, 2025, reporting other events and financial statements. The filing details the company's corporate structure, including i
• Genprex, Inc. Files 2024 Annual Report — 10-K · Apr 1, 2025 Risk: medium
  Genprex, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, based in Austin, TX, operates in the Pharmaceutical Preparations sector.
• Genprex, Inc. Files 8-K: Material Agreements and Other Events — 8-K · Feb 18, 2025 Risk: medium
  On February 17, 2025, Genprex, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also
• Genprex Faces Potential Delisting Concerns — 8-K · Feb 12, 2025 Risk: high
  Genprex, Inc. filed an 8-K on February 12, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicate
• Genprex, Inc. Files 8-K Report — 8-K · Jan 23, 2025 Risk: low
  On January 23, 2025, Genprex, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details regarding the
• Genprex, Inc. Files 8-K — 8-K · Jan 13, 2025 Risk: low
  Genprex, Inc. filed an 8-K on January 13, 2025, reporting on financial statements and exhibits. The filing does not contain specific financial figures or operat
• Genprex, Inc. Files 8-K: Other Events & Financials — 8-K · Dec 16, 2024 Risk: low
  Genprex, Inc. filed an 8-K on December 16, 2024, reporting other events and financial statements. The company, incorporated in Delaware with its principal execu
• Genprex, Inc. Files 8-K: Other Events & Financials — 8-K · Nov 20, 2024 Risk: low
  Genprex, Inc. filed an 8-K on November 20, 2024, reporting other events and financial statements. The company, incorporated in Delaware with its principal execu
• Genprex Faces Delisting Concerns — 8-K · Nov 19, 2024 Risk: high
  Genprex, Inc. filed an 8-K on November 19, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicate
• Genprex 10-Q: Focus on Future Funding Amidst Operating Losses — 10-Q · Nov 13, 2024 Risk: high
  Genprex, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported minimal revenue and significant operating losses, consistent with it
• Genprex, Inc. Files 8-K with Office and Contact Updates — 8-K · Nov 5, 2024 Risk: low
  Genprex, Inc. filed an 8-K on November 5, 2024, reporting other events and financial statements. The filing details the company's principal executive offices lo
• SC 13G/A Filing — SC 13G/A · Oct 24, 2024
• Genprex, Inc. Files 8-K: Corporate Details — 8-K · Oct 24, 2024 Risk: low
  Genprex, Inc. filed an 8-K on October 24, 2024, reporting other events and financial statements. The filing details the company's corporate structure, including
• SC 13G Filing — SC 13G · Oct 22, 2024
• Genprex, Inc. Files 8-K with Corporate Updates — 8-K · Oct 15, 2024 Risk: low
  Genprex, Inc. filed an 8-K on October 15, 2024, reporting on other events and financial statements. The filing details the company's corporate structure, includ
• SC 13G Filing — SC 13G · Oct 3, 2024
• Genprex, Inc. Files 8-K on Delisting Concerns — 8-K · Sep 26, 2024 Risk: high
  Genprex, Inc. filed an 8-K on September 26, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The filing also includes finan
• Genprex, Inc. Files 8-K with Corporate Updates — 8-K · Sep 4, 2024 Risk: low
  Genprex, Inc. filed an 8-K on September 4, 2024, reporting other events and financial statements. The filing details the company's corporate structure, includin
• Genprex, Inc. Files 8-K with Corporate Updates — 8-K · Aug 13, 2024 Risk: low
  Genprex, Inc. filed an 8-K on August 13, 2024, reporting other events and financial statements. The filing details the company's corporate structure, including
• Genprex, Inc. Q2 2024 10-Q Filing — 10-Q · Aug 9, 2024 Risk: medium
  Genprex, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $179,550 as of June 30, 2024. The filing details financia

Related Companies

AZN · MRK · RHHBY

Frequently Asked Questions